News Releases

News Releases

Nov 23, 2020
NEEDHAM, Mass. , Nov. 23, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases on burdensome and painful
Nov 18, 2020
91% of patients on MYCAPSSA maintained IGF-1 response in the 9-month randomized , controlled   phase   of the non-inferiority trial C ompany intends to submit a marketing application for MYCAPSSA in the EU in mid-2021 Company to host conference call today at 8 : 00 a .m. ET NEEDHAM, Mass. , Nov.
Nov 16, 2020
NEEDHAM, Mass. , Nov. 16, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases on burdensome and painful
Nov 05, 2020
L aunched   MYCAPSSA ® in U.S.   earlier than expected and recognized first net product revenues   in September Well capitalized to support the MYCAPSSA launch On track to announce MPOWERED ™ Phase 3 trial topline data this month Company to host conference call today, November 5 , 2020   at 5 :00
Oct 29, 2020
Company to host conference call and webcast at 5:00 p.m. ET NEEDHAM, Mass. , Oct. 29, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced that it will host a conference call and live audio webcast on Thursday, November 5, 2020 at 5:00
Oct 01, 2020
Mark Fitzpatrick to Step Down as President and Principal Financial Officer Following the Appointment of a New Chief Financial Officer NEEDHAM, Mass. , Oct. 01, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform
Sep 08, 2020
NEEDHAM, Mass. , Sept. 08, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therapies to reduce the burden of chronic injections for people with rare diseases, today announced that
Aug 03, 2020
Company to host conference call and webcast at 5:00 p.m. ET NEEDHAM, Mass. , Aug. 03, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced that it will host a conference call and live audio webcast on Monday, August 10, 2020 at 5:00
May 07, 2020
Remain on Track with MYCAPSSA® Anticipated June 26, 2020 PDUFA Date and Planned U.S. Commercial Launch in Q4’20 NEEDHAM, Mass. , May 07, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical, late-stage biopharmaceutical company focused on improving the lives of patients who face
Apr 30, 2020
Company to host conference call and webcast at 5:00 p.m. ET NEEDHAM, Mass. , April 30, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical, late-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it
Mar 16, 2020
MYCAPSSA ® PDUFA Date Set for June 26, 2020 ; U.S. Commercial Launch Planned in Q4’20 First Industry Sponsored U.S. Disease State Registry for Acromegaly Began Enrolling Patients NEEDHAM, Mass. , March 16, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical stage biopharmaceutical
Jan 10, 2020
MYCAPSSA ® NDA resubmitted to FDA ; PDUFA decision expected mid-2020 MYCAPSSA ® U.S. commercial launch planned for the fourth quarter of 2020 Top-line MYCAPSSA ® MPOWERED Phase 3 results on track for the fourth quarter of 2020 NEEDHAM, Mass. , Jan. 10, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc.

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent filings with the U.S. Securities and Exchange Commission.

Shareholder Tools